Partners
The ERA4TB Consortium brings together a multi-disciplinary team with proven expertise and capabilities in TB drug development to profile and progress anti-TB compounds up to completion of Phase I.
The project consortium integrates 31 organizations, namely eight prestigious academic institutions (UC3M, UNIZAR, UU, EPFL, UKÖ, UNIPD, UPV, LUND), four non-profit organizations (IPP, IPL, iM4TB, BAR), eight public research organizations (FZB, CNR, IDMIT, SERMAS, PHE, NICE, SCI, IOS) and five highly skilled small-medium enterprises (SYNAPSE, C-Path, IBT, QPS, GRIT42), together with three EFPIA members (GSK, EVT, JANSSEN), and three IMI2 Associated Partners (BMGF, TBA, DDU).
Collaborating Partners
Coming Soon
Advisors
Coming Soon
Know how accelerate the development of new treatment regimens for tuberculosis, discover our project
The Project
